Group 1 - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - The early trading volume in Hong Kong stocks reached 160.2 billion HKD [1] Group 2 - New pharmaceutical stocks in the Hong Kong Stock Connect saw significant gains, with ZhiJie AnKang-B (02617) surging over 49%, reaching a market capitalization of over 240 billion HKD; BaiZe Medical (02609) rose over 76%; and TongYuanKang Pharmaceutical-B (02410) increased by over 36% [1] - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at 1.35 HKD, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company well-prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose over 6% as its "SoFast" service officially launched in Macau, with Daiwa optimistic about the company's revenue growth prospects [2] - Valiant Bio-B (09887) increased by over 13%, with its core product LBL-024 for melanoma completing its first patient dosing in trials [2] - Bilibili-W (09626) rose by 2.78%, accumulating a total increase of about 25% over the past six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - LionTeng Holdings (02562) surged over 7% as it plans to acquire leading companies in artificial intelligence and blockchain to expand its digital finance layout [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted placement to raise approximately 5.392 billion HKD for structural adjustments in polysilicon capacity [2] - China General Nuclear Power Corporation Mining (01164) increased by 6.7%, as the U.S. seeks to expand its strategic uranium reserves, with institutions expecting a recovery in uranium prices [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted placement to raise about 1.15 billion HKD [2]

Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, focusing on specific companies and their recent performance, driven by various strategic announcements and market conditions. Hong Kong Stock Market Summary - China General Nuclear Power Corporation (01164) rose over 6% following US Energy Secretary Chris Wright's suggestion to consider expanding strategic uranium reserves, indicating potential upward price adjustments for uranium [1] - Yunfeng Financial (00376) fell over 18% after announcing a rights issue at a discount of approximately 16.8%, aiming to raise about HKD 1.15 billion [1] - GCL-Poly Energy Holdings (03800) increased over 2% as it plans a rights issue at a discount of about 8.73%, targeting net proceeds of HKD 5.392 billion for structural adjustments in polysilicon production [1] - Lion Group Holding (02562) surged over 6% after signing a letter of intent to acquire a leading AI and blockchain company, expanding its digital finance footprint [1] - Pharmaron Beijing Co., Ltd. (02617) skyrocketed over 53% after being included in the Hong Kong Stock Connect list, with a cumulative increase of nearly 10 times since its inclusion, and northbound investors adding over HKD 300 million in two days [1] - Anta Sports Products (02020) rose over 2% as retail sales of sports goods showed rapid growth in the first eight months, indicating marginal improvement in sales [1] - SF Technology (09699) increased over 5% after launching its "SoFast" brand in Macau, marking a significant step in its overseas business expansion [1] - Shanghai Fudan (01385) rose over 6% as Morgan Stanley reported the company is well-prepared for supply chain disruptions, with limited demand impact expected [2] - Tianyue Advanced (02631) increased over 1% after being included in the Hong Kong Stock Connect, with silicon carbide expected to see new market growth [2] - Valiant Co., Ltd. (09887) rose over 10% after announcing the completion of the first patient dosing in a trial for its core product LBL-024 for melanoma [2] US Stock Market Summary - Tesla (TSLA.US) rose 3.56% as the head of its German factory announced an increase in production plans for Q3 and Q4 due to strong sales data [3] - NVIDIA (NVDA.US) fell 0.04% as it faces further investigation for violating antitrust laws [3] - Hesai Technology (HSAI.US) increased 4.31% after announcing a partnership with a leading US Robotaxi company, securing over USD 40 million in lidar orders [3] - XPeng Motors (XPEV.US) rose 2.20% after formalizing a deep cooperation with Magna Steyr in Austria, marking the start of local production in Europe [3] - NIO (NIO.US) increased 4.34% as it announced the NIO Day 2025 event, scheduled for September 20, where the new ES8 will be launched [3] - Apple (AAPL.US) rose 1.12% as Morgan Stanley reported that demand for the iPhone 17 series exceeded that of the previous year's iPhone 16 series during its first week of launch [4] - Fangdd Network Group (DUO.US) fell 9.17% following the National Bureau of Statistics' report indicating a decline in residential property prices in August [3] - Alibaba (BABA.US) rose 1.92% ahead of the 2025 Cloud Summit scheduled for September 24-26 in Hangzhou [4] - ASML Holding (ASML.US) increased 6.56% after announcing a EUR 1.3 billion investment in French AI startup Mistral AI, becoming its largest shareholder [4] - Bilibili (BILI.US) rose 6.40% as it announced the upcoming public test of its new strategy card game, "Three Kingdoms: Hundred Generals Card" [4] - Oracle (ORCL.US) increased 3.41% as management disclosed that its cloud infrastructure revenue is set to experience steep growth [4]

每经AI快讯，9月16日，港股维立志博-B(09887.HK)早盘涨超10%，截至发稿，涨8.04%，报69.85港 元，成交额7690.52万港元。 ...

公开资料显示，维立志博目前拥有14款候选药物，其中6款已进入临床阶段，包括1款核心产品及3款主 要产品。核心产品LBL-024是一款处于注册临床阶段的PD-L1与4-1BB双特异性抗体，公司目前正在评 估LBL-024对晚期肺外神经内分泌癌、小细胞肺癌、胆道癌、非小细胞肺癌及其他实体瘤的潜在疗效。 消息面上，维立志博近日公告称，自主研发的奥帕替苏米单抗(LBL-024,抗PD-L1/4-1BB双特异性抗体) 顺利完成一项Ib/Ⅱ期临床研究(NCT07099430)首例患者入组，该研究将探索奥帕替苏米单抗单药或联合 用药治疗一线晚期黑色素瘤。据悉，LBL-024为针对肺外神经内分泌癌的全球首款达到注册临床阶段的 靶向4-1BB受体的疗法，亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。 维立志博-B(09887)早盘涨超10%，截至发稿，涨8.04%，报69.85港元，成交额7690.52万港元。 ...

公开资料显示，维立志博目前拥有14款候选药物，其中6款已进入临床阶段，包括1款核心产品及3款主 要产品。核心产品LBL-024是一款处于注册临床阶段的PD-L1与4-1BB双特异性抗体，公司目前正在评 估LBL-024对晚期肺外神经内分泌癌、小细胞肺癌、胆道癌、非小细胞肺癌及其他实体瘤的潜在疗效。 智通财经APP获悉，维立志博-B(09887)早盘涨超10%，截至发稿，涨8.04%，报69.85港元，成交额 7690.52万港元。 消息面上，维立志博近日公告称，自主研发的奥帕替苏米单抗（LBL-024, 抗PD-L1/4-1BB双特异性抗 体）顺利完成一项Ib/Ⅱ期临床研究（NCT07099430）首例患者入组，该研究将探索奥帕替苏米单抗单 药或联合用药治疗一线晚期黑色素瘤。据悉，LBL-024为针对肺外神经内分泌癌的全球首款达到注册临 床阶段的靶向4-1BB受体的疗法，亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。 ...

Core Viewpoint - The stock of Valiant Biosciences-B (09887) rose over 5% following the announcement of the first patient enrollment in a Phase Ib/II clinical trial for LBL-024, a dual-specific antibody targeting PD-L1/4-1BB for the treatment of advanced melanoma [1] Group 1: Company Developments - Valiant Biosciences announced the successful enrollment of the first patient in the Phase Ib/II clinical trial (NCT07099430) for LBL-024, which will explore its use as a monotherapy or in combination for first-line treatment of advanced melanoma [1] - LBL-024 is noted as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally, with potential to become the first approved drug for advanced pulmonary neuroendocrine carcinoma [1] Group 2: Market Reaction - Following the announcement, Valiant Biosciences' stock price increased by 4.84%, reaching 65 HKD, with a trading volume of 22.107 million HKD [1] Group 3: Research and Development Focus - CMB International previously released a report highlighting Valiant Biosciences' focus on developing immunotherapies involving immune checkpoint inhibitors and co-stimulatory agonists, while also expanding into other areas such as CD3 T cell connectors and antibody-drug conjugates (ADC) [1] - The company has developed proprietary platforms, LeadsBody and X-body, which serve as engines for continuous drug discovery [1] - The firm is optimistic about the development of PD-L1/4-1BB and TCE as next-generation immuno-oncology therapies [1]

Core Viewpoint - The stock of Valiant Biopharma-B (09887) rose over 5% following the announcement of successful patient enrollment in a clinical study for its drug LBL-024, a dual-specific antibody targeting PD-L1 and 4-1BB, which is aimed at treating advanced melanoma and potentially lung neuroendocrine cancer [1] Company Developments - Valiant Biopharma announced the successful enrollment of the first patient in an Ib/II clinical study (NCT07099430) for LBL-024, which will explore its efficacy as a monotherapy or in combination for first-line treatment of advanced melanoma [1] - LBL-024 is noted as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally, with the potential to become the first approved drug for advanced lung neuroendocrine cancer [1] Industry Insights - CMB International released a report highlighting Valiant Biopharma's focus on developing immunotherapies involving immune checkpoint inhibitors and co-stimulatory agonists, while also expanding into other areas such as CD3T cell connectors and antibody-drug conjugates (ADC) [1] - The company has developed proprietary platforms, LeadsBody and X-body, which serve as engines for continuous drug discovery [1] - The report expresses optimism regarding Valiant Biopharma's development of PD-L1/4-1BB and TCE as next-generation immuno-oncology therapies [1]

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) highlights the initiation of a Phase Ib/II clinical trial for the drug Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) in treating advanced melanoma, marking a significant step in cancer therapy development [1] Group 1 - The Phase Ib/II multi-center clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals across the country [1] - The trial aims to evaluate the efficacy and safety of Opalizumab as a monotherapy or in combination with other agents for the treatment of advanced melanoma [1]

维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)单药或联合其 他药剂用于一线治疗晚期黑色素瘤的Ib/Ⅱ期临床试验(NCT07099430)首例患者已成功用药。 本次开展的Ib/Ⅱ期、多中心临床试验由福建省肿瘤医院陈誉教授牵头，全国多家医院共同参与。该试 验旨在评价奥帕替苏米单抗单药或联合用药治疗晚期黑色素瘤的疗效及安全性。 ...